covid-19. COVID-19, virus identified.
Conditions
Interventions
Intervention 1: Intervention group: The magnesium citrate supplement is taken as a 300 mg capsule once a day for 1 month. Intervention 2: Control group: The placebo is taken as a capsule containing 30
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Laboratory confirmation of Covid-19 (2019-nCoV Real-Time RT-PCR) Patients with moderate status Age from 18 to 65 years gender: male/female
Exclusion criteria
Exclusion criteria: Hospitalization of the patient in the intensive care unit Underlying diseases such as diabetes, hypertension, cardiovascular disease, kidney disease and mental disorders such as depression Obesity (BMI = 30) Vitamin D level less than 30 ng / ml Hypomagnesemia (magnesium level less than 1.7 mg / dL) and hypermagnesemia (magnesium level higher than 2.6 mg / dL) Pregnancy and lactation Contraindications, intolerance or allergy to magnesium Taking dietary supplements Alcohol and drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Oxygen saturation. Timepoint: First and 30 days after the intervention. Method of measurement: using pulse oximeter device.;Respiratory rate. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Fever. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Rate of lung involvement. Timepoint: First and 30 days after the intervention. Method of measurement: CT scan of the chest.;Duration of hospitalization. Timepoint: First and 30 days after the intervention. Method of measurement: Counting the days of hospitalization.;Hs-CRP. Timepoint: First and 30 days after the intervention. Method of measurement: Based on laboratory measurements-mg/l.;TNF-a. Timepoint: First and 30 days after the intervention. Method of measurement: Based on laboratory measurements-mg/l.;CBC. Timepoint: First and 30 days after the intervention. Method of measurement: Cell counter.;Final status of the patient. Timepoint: First and 30 days after the intervention. Method of measurement: Dead / Alive.;Depression. Timepoint: First and 30 days after the intervention. Method of measurement: questionnaire scoring(BDI-II).;Anxiety. Timepoint: First and 30 days after the intervention. Method of measurement: questionnaire scoring(STAI).;Quality of Life. Timepoint: First and 30 days after the intervention. Method of measurement: questionnaire scoring(sf-36). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Rostami
Ahvaz University of Medical Sciences
Outcome results
None listed